Evidence map›Paper›PMID 36111288›Full record

ArticleSchizophrenia research. Cognition2022

Dispersion of cognitive performance test scores on the MATRICS Consensus Cognitive Battery: A different perspective.

David J Williamson, Keith H Nuechterlein, Todd Tishler, Joseph Ventura, Benjamin M Ellingson, Ibrahim Turkoz, Richard S E Keefe, Larry Alphs

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Schizophrenia research. Cognition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02431702 (A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02431702 phase3completednot on this map

A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics

TypeinterventionalSponsorJanssen Scientific Affairs, LLCRan2015 to 2019Enrolled337ConditionsSchizophrenia, Psychotic DisordersArmsAripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

David J WilliamsonJanssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA.
Keith H NuechterleinDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, 300 UCLA Medical Plaza, Los Angeles, CA 90095, USA.
Todd TishlerDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, 300 UCLA Medical Plaza, Los Angeles, CA 90095, USA.
Joseph VenturaDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, 300 UCLA Medical Plaza, Los Angeles, CA 90095, USA.
Benjamin M EllingsonDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, 300 UCLA Medical Plaza, Los Angeles, CA 90095, USA.
Ibrahim TurkozJanssen Research and Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA.
Richard S E KeefeDuke University Medical Center, 10 Duke Medicine Cir., Durham, NC 27710-1000, USA.
Larry AlphsJanssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA.
University of California, Los Angeles · USJanssen (United States) · USJanssen Scientific Affairs (United States)Verasci (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Persons with schizophrenia exhibit greater neurocognitive test score dispersion. Here, we seek to characterize dispersion on the Neurocognitive Composite subtests of the Measurement of Treatment Research to Improve Cognition in Schizophrena Consensus Cognitive Battery (MCCB) and determine the relative effects of different antipsychotic formulations on dispersion and mean performance. Method: In this post hoc analysis of the DREaM study (NCT02431702), which compared treatment with paliperidone palmitate (PP) long-acting injectable with oral antipsychotic (OAP) treatment over 18 months, dispersion in MCCB neurocognitive subtest performance was calculated for each participant by visit (test occasion). Results: Over 18 months, mean neurocognitive performance improved in a manner consistent with the expected effects of practice in both groups ( Conclusion: Dispersion of neurocognitive test scores provides a different index of cognitive change than that provided by composite scores. Long-term maintenance of therapeutic levels provided by PP over time may limit (relative to oral AP) the extent to which cognitive performance becomes more variable.

Indexed as

CognitionDispersionLong-acting injectable antipsychoticMATRICS Consensus Cognitive BatteryPaliperidone palmitateSchizophrenia

Identifiers

PMID36111288
PMCPMC9468588
OpenAlexW4294591017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.